Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Neutropenia
Interventions: DRUG: F-627|DRUG: Neulasta
Sponsor: EVIVE Biotechnology